Drugs / 1-desamino-8-D-arginine vasopressin
1-desamino-8-D-arginine vasopressin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03136003 | Jul 2017 → Aug 2018 | mild hemophilia A | The Hospital for Sick Children | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1-desamino-8-D-arginine vasopressin | “FVIII levels temporarily rise with stress, exercise and with DDAVP (1-desamino-8-D-arginine vasopressin, desmopressin).” NCT03136003 ↗ |
| Known as | DDAVP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03136003 ↗ |
| Known as | desmopressin | “FVIII levels temporarily rise with stress, exercise and with DDAVP (1-desamino-8-D-arginine vasopressin, desmopressin).” NCT03136003 ↗ |
| Route | Intranasal | “The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada).” NCT03136003 ↗ |